To include your compound in the COVID-19 Resource Center, submit it here.

New shot at sepsis

How Critical Pressure’s CPL001 could stabilize septic shock patients

Critical Pressure Ltd. is developing a therapy for septic shock to combat hypotension more effectively than marketed vasopressors, and without their side effects.

Sepsis is a systemic inflammatory response triggered by severe bacterial infection. Over 30% of patients with sepsis develop septic shock, which is characterized by severe hypotension that can lead to tissue damage, multiple organ failure and death.

Vasopressors, particularly those based on endogenous vasoconstrictors like norepinephrine, are used

Read the full 709 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE